The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of concurrent CYP3A4 interacting medications on ibrutinib outcomes in patients with CLL.
 
Adam Kittai
No Relationships to Disclose
 
Ashray Maniar
No Relationships to Disclose
 
Max J Gordon
No Relationships to Disclose
 
Michael Churnetski
No Relationships to Disclose
 
Xavier Rivera
No Relationships to Disclose
 
Hamood Alqahtani
No Relationships to Disclose
 
Sheila Hoff
Speakers' Bureau - Genentech
 
Douglas Rice
No Relationships to Disclose
 
Gregory Rice
No Relationships to Disclose
 
Daniel Oscar Persky
Consulting or Advisory Role - Cardinal Health; Genentech; MorphoSys; Spectrum Pharmaceuticals; Verastem
Speakers' Bureau - Gilead Sciences
Research Funding - Merck (Inst)
 
Michael Y. Choi
Consulting or Advisory Role - Abbvie/Genentech; Novartis
Speakers' Bureau - Abbvie/Genentech; Gilead Sciences; Pharmacyclics
Research Funding - Abbvie (Inst); Pharmacyclics (Inst)
 
Jonathon Brett Cohen
Consulting or Advisory Role - Abbvie; Celgene; Infinity Pharmaceuticals; Millennium; Novartis; Pharmacyclics; Seagen
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Takeda
 
Alexey Valeryevich Danilov
Stock and Other Ownership Interests - Abbvie
Honoraria - Dava Oncology; Prime Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech/Roche; Gilead Sciences; Juno Therapeutics; TG Therapeutics; Verastem
Research Funding - Genentech/Roche; Gilead Sciences; Takeda
Travel, Accommodations, Expenses - Genentech/Roche